1,820 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Purchased by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,820 shares of the medical research company's stock, valued at approximately $336,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Versant Capital Management Inc grew its stake in shares of Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after purchasing an additional 150 shares during the period. Assetmark Inc. boosted its position in shares of Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock worth $37,000 after buying an additional 173 shares in the last quarter. Pinnacle Bancorp Inc. boosted its position in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after buying an additional 65 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Charles River Laboratories International in the 3rd quarter worth about $59,000. Finally, ORG Wealth Partners LLC purchased a new stake in shares of Charles River Laboratories International in the 4th quarter worth about $56,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Trading Up 4.1 %

CRL traded up $6.93 on Friday, reaching $176.20. 1,169,106 shares of the company's stock were exchanged, compared to its average volume of 699,906. The company's 50 day moving average is $169.15 and its 200-day moving average is $185.63. The company has a market cap of $9.01 billion, a price-to-earnings ratio of 1,174.68, a PEG ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $274.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Remove Ads

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company's revenue was down 1.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.46 EPS. Equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other news, COO Birgit Girshick acquired 1,514 shares of the stock in a transaction on Thursday, February 20th. The stock was bought at an average price of $164.63 per share, with a total value of $249,249.82. Following the completion of the transaction, the chief operating officer now directly owns 55,058 shares of the company's stock, valued at $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Morgan Stanley decreased their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective on the stock in a research report on Monday, March 3rd. JPMorgan Chase & Co. reduced their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. Robert W. Baird reduced their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. Finally, Barclays reduced their target price on shares of Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $198.36.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).